Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Vaxcyte (PCVX) Accumulated Depreciation & Amortization (2019 - 2025)

Vaxcyte (PCVX) has 7 years of Accumulated Depreciation & Amortization data on record, last reported at $16.4 million in Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 134.19% to $16.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.4 million, a 134.19% increase, with the full-year FY2025 number at $16.4 million, up 134.19% from a year prior.
  • Accumulated Depreciation & Amortization reached $16.4 million in Q4 2025 per PCVX's latest filing, up from $7.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for PCVX hit a ceiling of $16.4 million in Q4 2025 and a floor of $300000.0 in Q1 2021.
  • A 5-year average of $2.6 million and a median of $1.5 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 280.0% in 2022, then crashed 57.89% in 2023.
  • Tracing PCVX's Accumulated Depreciation & Amortization over 5 years: stood at $1.8 million in 2021, then skyrocketed by 57.44% to $2.8 million in 2022, then grew by 12.91% to $3.2 million in 2023, then surged by 118.84% to $7.0 million in 2024, then surged by 134.19% to $16.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for PCVX at $16.4 million in Q4 2025, $7.0 million in Q4 2024, and $1.8 million in Q3 2024.